Recent Progress Of Individualized Antiplatelet Therapy After PCI For Coronary Heart Disease Patients

Coronary heart disease had become one of the major cardiovascular disease in our country. Percutaneous coronary intervention was the most importatn important method to treat severe coronary heart diseases. The postoperative double antiplatelet drugs were necessary to reduce the stent thrombosis events incidence after PCI which was promoted by worldwide guidelines. Clopidogrel was one of the most used antiplatelet drugs, but a lot of study showed that there were still a high stent thrombosis incidence even receiving enough clopidogrel treatment. Which may be explained by the platelet resistance(high on- treatment platelet reactivity, HTPR).For patients with HTPR, the results are controversial as to increasing clopidogrel dose or changing for other drugs can improve the HTPR. In this article, we reviewed the HTPR screening method, the application of new antiplatelet drugs and its effects on the prognosis of the patients.